Clinical trial NCT02145299: The Lumen Study: Comparing Devices for Patients With Symptomatic Femoro-popliteal Chronic Total Occlusion (CTO)
Official title: A Prospective, Multicenter, Open Label Randomized Study to Evaluate the Safety, Performance and Intraluminal Crossing of the TruePath™ CTO Device Versus The Crosser System in Patients With Symptomatic Femoro-popliteal Chronic Total Occlusion (CTO)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Symptomatic Femoro-popliteal Chronic Total Occlusion
Lead sponsor: Yale University
Sponsor class: OTHER
Collaborators: name: Boston Scientific Corporation
First posted: 2014-05-22
Enrollment: 8
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a prospective, multicenter, randomized, single-blind study enrolling up to 75 subjects at up to 5 sites in the US. Eligible subjects with symptomatic femoro-popliteal CTO will be randomized 2:1 to treatment with the TruePath™ CTO Device (Intervention) or the CROSSER™ CTO device (Control). All patients will receive standard anticoagulation per hospital protocol and antiplatelet therapy with aspirin and clopidogrel.

Detailed description: The primary objective of the study is to compare the technical success and in-hospital safety of TruePath device with that of the CROSSER device in patients with symptomatic femoro-popliteal CTO. Subjects will be followed clinically while in the hospital and at 1 month following the index procedure. All subjects will undergo procedural intravascular ultrasound (IVUS) imaging. The study population will consist of up to 75 patients with symptomatic femoro-popliteal CTO and indications for revascularization. Subjects must have a previously documented conventional percutaneous procedure or a concurrent failed attempt to cross the CTO using conventional guidewire techniques. All subjects must meet all inclusion and no exclusion criteria and sign an Informed Consent Form approved by the local Institutional Review Board (IRB) prior to enrollment and randomization.

Eligibility criteria: Inclusion Criteria:

* Clinical Inclusion Criteria
* Male or non-pregnant female ≥18 years of age;
* Rutherford Clinical Category 2-5
* Patients is willing to provide informed consent and comply with the required follow-up visits, testing schedule, and medication regimen
* Angiographic Lesion Inclusion Criteria
* Length ≤35 cm
* The lesion is a single lesion or composite of multiple lesions within the 35 cm segment
* 100% stenosis by visual estimate
* Previously documented conventional percutaneous procedure or a concurrent failed attempt to cross the CTO using conventional guidewire techniques
* Ability to visualize target artery distal to the lesion (via collateral circulation)
* Target lesion located in the superficial femoral/proximal popliteal arteries, with lesion location starting ≥1cm below the common femoral bifurcation
* De novo lesion or restenotic lesion \>30 days from any prior endovascular intervention
* Target vessel diameter ≥4 and ≤7 mm and able to be treated with PTA and or a stent
* A patent inflow artery free from significant lesions (≥50% stenosis) as confirmed by angiography. Treatment of the target lesion may be performed after successful treatment of existing inflow artery lesions at the time of the index procedure. \[NOTE: Successful inflow artery treatment is defined as attainment of residual diameter stenosis ≤50% without death or major vascular complication.\]
* At least one patent outflow artery free from significant lesion (≥50% stenosis) as confirmed by angiography (treatment of outflow disease is permitted)

Exclusion Criteria:

* Pregnant or nursing subjects and those who plan pregnancy in the period up to 3 months following index procedure. Female subjects of child-bearing potential must have a negative pregnancy test done prior to the index procedure.
* Rutherford Class 0, 1 or 6
* History of hemorrhagic stroke within 3 months
* Renal failure or chronic kidney disease with MDRD GFR ≤ 30 ml/min per 1.73m2 (or serum creatinine ≥2.5 mg/L within 30 days of index procedure or treated with dialysis)
* Previous or planned surgical or interventional procedure to the target limb within 2 weeks before (aside from conventional percutaneous procedure during the current hospitalization) or within 30 days after the index procedure
* Prior vascular surgery of the index limb, with the exception of common femoral patch angioplasty remote from the target lesion
* Planned use of adjunctive primary treatment modalities (e.g., laser, atherectomy, cryoplasty, scoring/cutting balloon, or other)
* Inability to take required study medications or an allergy to contrast that cannot be controlled with medication
* Life expectancy of \<1 years
* Patient is currently participating in an investigational drug or device study or previously enrolled in this study Subject enrollment and treatment

Primary outcomes:
measure: Technical Success
timeFrame: Day of operation
measure: In-hospital Safety
timeFrame: Operation through 30 day follow up
Secondary outcomes:
measure: Procedural Success
timeFrame: Day of operation
measure: Clinical Success
timeFrame: Day of operation
measure: Symptomatic Improvement
timeFrame: Baseline, and 30 days post operation
measure: Walking Capacity
timeFrame: Baseline and 30 days post operation
measure: Index Limb Amputation
timeFrame: Day of Operation through 30 days post operation
measure: Target Lesion Revascularization
timeFrame: 30 days post operation
measure: Ankle-brachial Index (ABI)
timeFrame: baseline to 30 days post operation
measure: Target Vessel Revascularization
timeFrame: 30 days post operation
measure: Angiographic Perforation Classification and Rate
timeFrame: Day of operation
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Yale Cardiovascular Research Group
state: Connecticut
Study officials:
affiliation: Yale University
name: Carlos Mena, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Yale University
name: Alexandra Lansky, MD
role: PRINCIPAL_INVESTIGATOR
References: